A biomarker analysis drawn from a randomized trial
The researchers studied anandamide, or AEA, a molecule in the endocannabinoid system, and lipopolysaccharide, or LPS, as primary outcomes. Cannabinoid receptor type 2, CB2R, and the enzyme FAAH were included in secondary or exploratory analyses.
The subsample included nine men who received hyperbaric oxygen therapy and eight controls. Treatment consisted of ten sessions, six per week, with exposure to pure oxygen at a pressure of 2.5 atmospheres absolute. Fasting blood samples were collected before and after the program.
The original trial was randomized, but this analysis relies on a selection made after randomization. Treated participants came from a subgroup scheduled for morning sessions. Controls were selected before the assays to improve comparability in baseline body mass index. This selection limits the strength of the comparison.
No significant difference in the markers measured
Changes in AEA, LPS, CB2R and FAAH did not differ significantly between groups. The researchers also observed no significant change within the treated group.
This result does not demonstrate that hyperbaric oxygen therapy has no biological effects whatsoever. It indicates that this analysis detected no change in these circulating markers under the conditions studied. The available abstract does not report the magnitudes of the differences or their confidence intervals, limiting assessment of their importance.
A baseline association that proves no mechanism
Before treatment, AEA and LPS concentrations were positively associated. This exploratory observation cannot establish whether one influences the other, nor can it support an inference about a treatment effect. The authors state that it needs to be confirmed in adequately powered studies.
Assessing the value of hyperbaric oxygen therapy also requires distinguishing a blood test result from a tangible benefit. This analysis demonstrates no improvement in symptoms, recovery or long-term health. Its findings also do not support conclusions about women, people with illnesses or other treatment programs.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. The sample is small, exclusively male, and the subsample was selected after randomization. Effect sizes and their confidence intervals are not provided in the abstract. Adverse effects, funding and conflicts of interest could not be verified.
What we can take away
These data do not support the idea that ten sessions of hyperbaric oxygen therapy alter the endocannabinoid markers and LPS measured in these active men. They remain too limited to rule out a modest effect or assess clinical benefit.
Sources and provenance
- A Pilot Investigation of Endocannabinoid System Markers and Lipopolysaccharide Responses to 10 Sessions of Hyperbaric Oxygen Therapy.
Source date: 2026-11-20.
Journal Article, Randomized Controlled Trial · Résumé PubMed uniquement, texte intégral non consulté


